Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2013, Article ID 719202, 8 pages
http://dx.doi.org/10.1155/2013/719202
Review Article

Associations of miR-499 and miR-34b/c Polymorphisms with Susceptibility to Hepatocellular Carcinoma: An Evidence-Based Evaluation

1Department of Hepatobiliary Surgery, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, China
2Jiangsu Province's Key Medical Center for Liver Surgery, Nanjing, Jiangsu 210008, China
3School of Medicine, Nanjing University, Nanjing, Jiangsu 210093, China
4Department of Hepatobiliary Surgery, Drum Tower Clinical Medical College of Nanjing Medical University, Nanjing, Jiangsu 210008, China

Received 24 July 2013; Accepted 27 August 2013

Academic Editor: Qiang Xia

Copyright © 2013 Zhongxia Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global cancer statistics,” CA Cancer Journal for Clinicians, vol. 61, no. 2, pp. 69–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. H. B. El-Serag, “Hepatocellular carcinoma,” The New England Journal of Medicine, vol. 365, no. 12, pp. 1118–1127, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Arzumanyan, H. M. G. P. V. Reis, and M. A. Feitelson, “Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma,” Nature Reviews Cancer, vol. 13, pp. 123–135, 2013. View at Google Scholar
  4. H. B. El-Serag and K. L. Rudolph, “Hepatocellular carcinoma: epidemiology and molecular carcinogenesis,” Gastroenterology, vol. 132, no. 7, pp. 2557–2576, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. D. P. Bartel, “microRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. T. A. Farazi, J. I. Hoell, P. Morozov et al., “MicroRNAs in human cancer,” Advances in Experimental Medicine and Biology, vol. 774, pp. 1–20, 2013. View at Google Scholar
  7. M. V. Iorio and C. M. Croce, “microRNA involvement in human cancer,” Carcinogenesis, vol. 33, pp. 1126–1133, 2012. View at Publisher · View at Google Scholar
  8. X. W. Wang, N. H. H. Heegaard, and H. Orum, “microRNAs in liver disease,” Gastroenterology, vol. 142, pp. 1431–1443, 2012. View at Publisher · View at Google Scholar
  9. C. M. Wong, A. K. L. Kai, F. H. C. Tsang, and I. O. Ng, “Regulation of hepatocarcinogenesis by microRNAs,” Frontiers in Bioscience (Elite Edition), vol. 5, pp. 49–60, 2013. View at Google Scholar
  10. S. Giordano and A. Columbano, “microRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma?” Hepatology, vol. 57, pp. 840–847, 2013. View at Publisher · View at Google Scholar
  11. F. Lovat, N. Valeri, and C. M. Croce, “MicroRNAs in the pathogenesis of cancer,” Seminars in Oncology, vol. 38, no. 6, pp. 724–733, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Gong, Y. Tong, H.-M. Zhang et al., “Genome-wide identification of SNPs in MicroRNA genes and the SNP effects on MicroRNA target binding and biogenesis,” Human Mutation, vol. 33, no. 1, pp. 254–263, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Bandiera, E. Hatem, S. Lyonnet, and A. Henrion-Caude, “microRNAs in diseases: from candidate to modifier genes,” Clinical Genetics, vol. 77, no. 4, pp. 306–313, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. H. Bender, L. C. Koenig, N. Joschko et al., “P53 is an important regulator of micrornas in hepatocellular carcinoma,” Hepatology, vol. 52, p. 951A, 2010. View at Google Scholar
  15. L. He, X. He, L. P. Lim et al., “A microRNA component of the p53 tumour suppressor network,” Nature, vol. 447, no. 7148, pp. 1130–1134, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. J.-X. Wang, J.-Q. Jiao, Q. Li et al., “MiR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1,” Nature Medicine, vol. 17, no. 1, pp. 71–78, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Akkiz, S. Bayram, A. Bekar et al., “Genetic variation in the microRNA-499 gene and hepatocellular carcinoma risk in a Turkish population: lack of any association in a case-control study,” Asian Pacific Journal of Cancer Prevention, vol. 12, pp. 3107–3112, 2011. View at Google Scholar
  18. W. H. Kim, K. T. Min, Y. J. Jeon et al., “Association study of microRNA polymorphisms with hepatocellular carcinoma in Korean population,” Gene, vol. 504, pp. 92–97, 2012. View at Google Scholar
  19. Y. Xiang, S. Fan, J. Cao, S. Huang, and L.-P. Zhang, “Association of the microRNA-499 variants with susceptibility to hepatocellular carcinoma in a Chinese population,” Molecular Biology Reports, vol. 39, pp. 7019–7023, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Zhou, R. Lv, X. Song et al., “Association between two genetic variants in miRNA and primary liver cancer risk in the Chinese population,” DNA and Cell Biology, vol. 31, no. 4, pp. 524–530, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. H.-Z. Zou and Y.-Q. Zhao, “Positive association between miR-499A>G and hepatocellular carcinoma risk in a Chinese population,” Asian Pacific Journal of Cancer Prevention, vol. 14, pp. 1769–1772, 2013. View at Google Scholar
  22. Y. Xu, L. Liu, J. Liu et al., “A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma,” International Journal of Cancer, vol. 128, no. 2, pp. 412–417, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. M. S. Son, M. J. Jang, Y. J. Jeon et al., “Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma,” Gene, vol. 524, pp. 156–160, 2013. View at Publisher · View at Google Scholar
  24. Y. F. Han, R. Pu, X. Han et al., “Associations of pri-miR-34b/c and pre-miR-196a2 polymorphisms and their multiplicative interactions with hepatitis B virus mutations with hepatocellular carcinoma risk,” PLoS One, vol. 8, no. 3, Article ID e58564, 2013. View at Google Scholar
  25. J. Lau, J. P. A. Ioannidis, and C. H. Schmid, “Quantitative synthesis in systematic reviews,” Annals of Internal Medicine, vol. 127, no. 9, pp. 820–826, 1997. View at Google Scholar · View at Scopus
  26. N. Mantel and W. Haenszel, “Statistical aspects of the analysis of data from retrospective studies of disease,” Journal of the National Cancer Institute, vol. 22, pp. 719–748, 1959. View at Google Scholar
  27. R. DerSimonian and N. Laird, “Meta-analysis in clinical trials,” Controlled Clinical Trials, vol. 7, no. 3, pp. 177–188, 1986. View at Google Scholar · View at Scopus
  28. D. L. White, F. Kanwal, and H. B. El-Serag, “Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review,” Clinical Gastroenterology and Hepatology, vol. 10, pp. 1342.e2–1359.e2, 2012. View at Google Scholar
  29. S. Huang and X. He, “The role of microRNAs in liver cancer progression,” British Journal of Cancer, vol. 104, no. 2, pp. 235–240, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. D. W. Salzman and J. B. Weidhaas, “SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer,” Pharmacology & Therapeutics, vol. 137, pp. 55–63, 2013. View at Google Scholar
  31. Z. Wang, Y. Cao, C. Jiang, G. Yang, J. Wu, and Y. Ding, “Lack of association of two common polymorphisms rs2910164 and rs11614913 with susceptibility to hepatocellular carcinoma: a meta-analysis,” PLoS One, vol. 7, Article ID e40039, 2012. View at Google Scholar
  32. K. Lafferty-Whyte, C. J. Cairney, N. B. Jamieson, K. A. Oien, and W. N. Keith, “Pathway analysis of senescence-associated miRNA targets reveals common processes to different senescence induction mechanisms,” Biochimica et Biophysica Acta, vol. 1792, no. 4, pp. 341–352, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Yang, J. Chen, Y. Li et al., “Association of polymorphisms in pre-miRNA with inflammatory biomarkers in rheumatoid arthritis in the Chinese Han population,” Human Immunology, vol. 73, no. 1, pp. 101–106, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. X. Q. Liu, Z. Zhang, L. Sun et al., “microRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4,” Carcinogenesis, vol. 32, no. 12, pp. 1798–1805, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. Z. Hu, J. Liang, Z. Wang et al., “Common genetic variants in pre-microRNAs were associated with increased risk of breast cancer in Chinese women,” Human Mutation, vol. 30, no. 1, pp. 79–84, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. B. Zhou, K. Wang, Y. Wang et al., “Common genetic polymorphisms in pre-microRNAs and risk of cervical squamous cell carcinoma,” Molecular Carcinogenesis, vol. 50, no. 7, pp. 499–505, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. Z. Liu, G. Li, S. Wei et al., “Genetic variants in selected pre-microRNA genes and the risk of squamous cell carcinoma of the head and neck,” Cancer, vol. 116, no. 20, pp. 4753–4760, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Daige, L. Priddy, K. Kelnar et al., “The development of a miRNA-based therapeutic candidate for hepatocellular carcinoma,” Molecular Cancer Therapeutics, vol. 10, no. 11, 2011. View at Google Scholar
  39. G. T. Bommer, I. Gerin, Y. Feng et al., “p53-mediated activation of miRNA34 candidate tumor-suppressor genes,” Current Biology, vol. 17, no. 15, pp. 1298–1307, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Toyota, H. Suzuki, Y. Sasaki et al., “Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer,” Cancer Research, vol. 68, no. 11, pp. 4123–4132, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. K.-I. Kozaki, I. Imoto, S. Mogi, K. Omura, and J. Inazawa, “Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer,” Cancer Research, vol. 68, no. 7, pp. 2094–2105, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Lujambio, G. A. Calin, A. Villanueva et al., “A microRNA DNA methylation signature for human cancer metastasis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 36, pp. 13556–13561, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. N. Tanaka, S. Toyooka, J. Soh et al., “Frequent methylation and oncogenic role of microRNA-34b/c in small-cell lung cancer,” Lung Cancer, vol. 76, no. 1, pp. 32–38, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. Z. Wang, Z. Chen, Y. Gao et al., “DNA hypermethylation of microRNA-34b/c has prognostic value for stage I non-small cell lung cancer,” Cancer Biology and Therapy, vol. 11, no. 5, pp. 490–496, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Vogt, J. Munding, M. Grüner et al., “Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas,” Virchows Archiv, vol. 458, no. 3, pp. 313–322, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. L.-B. Gao, L.-J. Li, X. M. Pan et al., “A genetic variant in the promoter region of miR-34b/c is associated with a reduced risk of colorectal cancer,” Biological Chemistry, vol. 394, pp. 415–420, 2013. View at Google Scholar
  47. L. Li, J. Wu, X. Sima et al., “Interactions of miR-34b/c and TP-53 polymorphisms on the risk of nasopharyngeal carcinoma,” Tumor Biology, vol. 34, pp. 1919–1923, 2013. View at Publisher · View at Google Scholar
  48. J. T. Bensen, C. K. Tse, S. J. Nyante et al., “Association of germline microRNA SNPs in pre-miRNA flanking region and breast cancer risk and survival: the Carolina Breast Cancer Study,” Cancer Causes Control, vol. 24, pp. 1099–1109, 2013. View at Publisher · View at Google Scholar
  49. P. Zou, L. Zhao, H. Xu et al., “Hsa-mir-499 rs3746444 polymorphism and cancer risk: a meta-analysis,” Journal of Biomedical Research, vol. 26, pp. 253–259, 2012. View at Publisher · View at Google Scholar
  50. Y. G. Zhang, J. X. Shi, and C. H. Song, “Association of mir-499 and mir-149 polymorphisms with cancer risk in the Chinese population: evidence from published studies,” Asian Pacific Journal of Cancer Prevention, vol. 14, pp. 2337–2342, 2013. View at Publisher · View at Google Scholar
  51. Y. Xu, L. Li, X. Xiang et al., “Three common functional polymorphisms in microRNA encoding genes in the susceptibility to hepatocellular carcinoma: a systematic review and meta-analysis,” vol. 527, no. 2, pp. 584–593, 2013. View at Google Scholar